NIH AI Restriction
NIH policy NOT-OD-25-132 prohibits the use of AI-generated text in grant applications that is not substantially modified by the applicant. All AI-drafted sections must be thoroughly rewritten in your own words before submission.
View full policyCollaborative Clinical Trials in Drug Abuse (R01)
About This Grant
-This Funding Opportunity Announcement (FOA) issued by the National Institute on Drug Abuse, National Institutes of Health, is a reissuance of PAR-04-073, Collaborative Clinical Trials in Drug Abuse, published in the NIH Guide for Contracts and Grants, March 9, 2004 at http://grants.nih.gov/grants/guide/pa-files/PAR-04-073.html. This announcement provides guidelines for the development, review, and funding of Collaborative Clinical Trials in Drug Abuse (CCTDA) through the solicitation of Research Project Grant (R01) applications from institutions/organizations that propose to carry out clinical trials using a common protocol at collaborating sites. One of the sites should be the coordinating site for the trial. Each site must submit a separate R01 application. Although a foreign institution may be a participating site, the coordinating site must be a domestic institution. -Purpose. The National Institute on Drug Abuse (NIDA) seeks to increase the collaboration of investigators at different sites in order to address critical issues in the treatment of substance-related disorders that require sample sizes greater than a single site can reasonably attain. The expectation for the collaborative effort is that there will be implementation of common clinical trials across different sites in order to study patient outcomes, patient factors, provider factors, setting characteristics, interactions of these, or other effects where pooled samples are appropriate and necessary for the hypotheses under consideration. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism.
Grant Summary
Collaborative Clinical Trials in Drug Abuse (R01) is a National Institutes of Health grant providing funding that varies by award for municipality. Applications are accepted on a rolling basis. Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
Requirements
- must submit a separate R01 application
How to Apply
Up to $0K
Rolling / Open
- 1Confirm your organization is eligible for Collaborative Clinical Trials in Drug Abuse (R01) from National Institutes of Health, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to National Institutes of Health before the deadline.
Search & build free — $99 one-time to unlock the export-ready application pack. No subscription.
Don't want to draft it yourself?
We'll draft the complete application against National Institutes of Health's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Collaborative Clinical Trials in Drug Abuse (R01): Frequently Asked Questions
Who is eligible for the Collaborative Clinical Trials in Drug Abuse (R01)?
Collaborative Clinical Trials in Drug Abuse (R01) is offered by National Institutes of Health and is generally open to municipality. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Collaborative Clinical Trials in Drug Abuse (R01) provide?
Collaborative Clinical Trials in Drug Abuse (R01) provides an amount that varies by award per award from National Institutes of Health. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Collaborative Clinical Trials in Drug Abuse (R01) deadline?
Collaborative Clinical Trials in Drug Abuse (R01) accepts applications on a rolling or ongoing basis, so there is no single fixed deadline. Confirm current timing with the funder, National Institutes of Health, before you apply, and submit as early as possible because rolling programs can close once funds are committed.
How do you apply for the Collaborative Clinical Trials in Drug Abuse (R01)?
To apply for Collaborative Clinical Trials in Drug Abuse (R01), confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from National Institutes of Health.